Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by tissue or cell testing, or by recognised clinical features
- People whose liver cancer has spread into the main portal vein (the large blood vessel that carries blood to the liver), confirmed by tissue testing or medical imaging
- People who have at least one liver tumour that can be measured using standard imaging criteria (RECIST version 1.1)
- People whose general physical functioning is rated at 2 or below on a standard 0–5 scale used by doctors to measure how much a condition limits daily activities (ECOG scale, where 0 means fully active and 5 means deceased)
- People who received a specific first-line treatment — either a combination of immune checkpoint inhibitors with a procedure called microwave thermal therapy, or a four-drug/procedure combination involving stent placement and portal vein reopening alongside immune and thermal treatments — within eight weeks of starting the study treatment (confirm with trial site for exact treatment details)
Who may not be able to join:
- People whose cancer has spread to parts of the body outside the liver
- People who have had, or currently have, another type of cancer
- People who received systemic treatments or local liver treatments (such as surgery, radiation, chemotherapy delivered to the liver artery, tumour embolisation, radiofrequency ablation, alcohol injection into the tumour, or cryoablation) within three months before starting the study treatment
- People with severely reduced liver function, a large amount of fluid build-up in the abdomen, or signs of a serious condition where the liver cannot remove toxins from the brain (hepatic encephalopathy)
- People whose medical records are incomplete or are missing key information needed for the study analysis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gaojun Teng, M.D., Zhongda Hospital
Phone: +86-15850654644
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.